Maria Asimopoulos

Marlboro

Editor at Physician's Weekly

Featured in: Favicon

hmpgloballearningnetwork.com Favicon

app.com

firstreportnow.com Favicon

physiciansweekly.com

Articles

How to Recognize & Manage Prolonged Grief Disorder

2 days ago | physiciansweekly.com | Maria Asimopoulos

Psychiatrists recommend effective ways for primary care physicians to screen for prolonged grief disorder and support patients with this condition. Many patients in primary care clinics and other healthcare settings experience comorbid mental health conditions. One that is often misunderstood or undetected is prolonged grief disorder. “For many people, the death of a loved one will be the single most stressful event of their life.
ADHD Diagnosis & Management Strategies for Primary Care, Part 2

4 days ago | physiciansweekly.com | Maria Asimopoulos

PeerPOV: The Pulse on Medicine is a weekly podcast series that features expert commentary on the latest healthcare news, landmark research, and more. Physician’s Weekly editorial board member Alex McDonald, MD, and psychiatrist Barry K. Herman, MD, continue their conversation about ADHD, offering resources that primary care physicians can use to become more comfortable with diagnosing and managing the condition in routine practice.
Outpatient Tarlatamab Administration Feasible in Relapsed SCLC With Close Monitoring

1 week ago | physiciansweekly.com | Maria Asimopoulos

Outpatient tarlatamab administration for relapsed small cell lung cancer was feasible and safe with proper monitoring, according to findings presented at ASCO. An abstract presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting described the feasibility and safety of administering tarlatamab in an outpatient setting for patients with small cell lung cancer (SCLC).
CLL Combo Therapy Maintains Safety, Efficacy Regardless of TP53 Status

1 week ago | physiciansweekly.com | Maria Asimopoulos

Zanubrutinib plus venetoclax showed promising efficacy and manageable safety in treatment-naïve CLL/SLL, including patients with del(17p) and TP53 mutations. At the 2025 ASCO Annual Meeting, Mazyar Shadman, MD, MPH, and colleagues presented findings from arm D of the SEQUOIA study, in which they evaluated zanubrutinib plus venetoclax in treatment-naïve patients with CLL/SLL.
Second-Line & Later Therapies Show Promising Outcomes in Small Cell Lung Cancer

2 weeks ago | physiciansweekly.com | Maria Asimopoulos

Lurbinectedin showed clinical benefit across therapy lines in small cell lung cancer, with best responses seen in later lines and with prior immunotherapy exposure. According to research presented at ASCO 2025, small cell lung cancer (SCLC) remains a particularly difficult disease to treat, with limited therapeutic options and generally poor survival outcomes.
Open Resection Linked to Margin Positivity After Lung Resection

2 weeks ago | physiciansweekly.com | Maria Asimopoulos

Open lung resection was linked to higher margin positivity rates than robotic surgery or VATS, with wedge resection and advanced disease also increasing risk. Rates of margin positivity after lung resection were no different between patients undergoing robotic surgery and video-assisted thoracoscopic surgery (VATS), according to a study published in Clinical Lung Cancer.
Mortality Benefits of Schizophrenia Meds May Be Overestimated

3 weeks ago | physiciansweekly.com | Maria Asimopoulos

A study suggests that failing to account for immortal time bias may misrepresent the mortality risks of psychiatric medications in schizophrenia. Observational studies that fail to account for immortal time bias (ITB) misinterpret the association between antipsychotics, antidepressants, and benzodiazepines and all-cause mortality in patients with schizophrenia, suggests a study published in JAMA Network Open.
SGLT2 Inhibitors Linked to Reduced CVD Risk in Type 2 Diabetes

3 weeks ago | physiciansweekly.com | Maria Asimopoulos

SGLT2 inhibitors reduced total cardiovascular risk by 18% in type 2 diabetes, with greatest benefit in patients at high risk for CVD recurrence. In patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2is) significantly decreased total cardiovascular disease (CVD) risk compared with dipeptidyl peptidase 4 inhibitors (DPP4is), according to a study published in JAMA Network Open.
Smoking Cessation Drops Risk for Hidradenitis Suppurativa Onset

1 month ago | physiciansweekly.com | Maria Asimopoulos |Seong Rae Kim

Smoking cessation significantly reduced the risk of hidradenitis suppurativa, while starting or resuming smoking matched the risk of continued smokers. Quitting smoking and maintaining smoking cessation were associated with a reduced risk of hidradenitis suppurativa (HS) development compared with continued smoking, according to a study published in JAMA Dermatology.
Do You Know About These Breast Cancer Trials?

1 month ago | physiciansweekly.com | Maria Asimopoulos

Breast cancer is the most common cancer in the United States, with more than 300,000 new cases estimated in 2025. In this article, Physician’s Weekly offers a roundup of current clinical trials investigating treatment regimens for patients with breast cancer.